UroGen Pharma (URGN) PT Raised to $40 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Price: $34.40 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Leland Gershell raised the price target on UroGen Pharma (NASDAQ: URGN) to $40.00 (from $34.00) while maintaining a Outperform rating.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
- Emcure Pharmaceuticals Limited (EMCURE:IN) PT Raised to INR2,200 at Axis Capital Limited
- Max Healthcare Institute Ltd (MAXHEALT:IN) PT Lowered to INR1,000 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
